Neuralink's Blindsight has no public trial record while rival vision implants publish patient data
Musk calls the implant ready from an engineering standpoint, Neuralink still lists future trials, and Cortigent and PRIMA have the published participant results Blindsight lacks.
By RuntimeWire Staff · Published
Primary source: Tom's Hardware
Why it matters
Blindsight would send information into the brain to create visual perception, a harder clinical and regulatory task than reading neural signals for computer control. Musk's engineering-readiness claim arrives without published Blindsight patient results, while Cortigent and Science Corporation are putting cohort data into the public record that regulators, clinicians and investors can compare.
Elon Musk (@elonmusk) said on October 30th that Neuralink's Blindsight implant is "ready from an engineering standpoint" and waiting on regulatory approval. Musk did not specify which engineering tests are complete or which regulatory decision remains. That narrower claim is the extent of the vision update, and it leaves Blindsight in a different position from Neuralink's programs that can point to named participants and published study activity.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.